![Yael Kenen](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Yael Kenen
Direttore Tecnico/Scientifico/R&S presso EPITOMEE MEDICAL LTD
Profilo
Yael Kenen is currently the Vice President-Clinical Affairs at Epitomee Medical Ltd.
Prior to this, Yael worked as the Chief Executive Officer at Lacrima Medical Ltd.
and as the Chief Operating Officer at TransPharma Medical Ltd.
Yael holds an MBA from Technion-Israel Institute of Technology and a doctorate from The Hebrew University of Jerusalem.
Posizioni attive di Yael Kenen
Società | Posizione | Inizio |
---|---|---|
EPITOMEE MEDICAL LTD | Direttore Tecnico/Scientifico/R&S | 01/01/2020 |
Precedenti posizioni note di Yael Kenen
Società | Posizione | Fine |
---|---|---|
Lacrima Medical Ltd.
![]() Lacrima Medical Ltd. Medical SpecialtiesHealth Technology Lacrima Medical Ltd. engages in the development of medical device for the treatment of chronic insomnia. The company was founded in 2013 and is headquartered in Tel Aviv, Israel. | Amministratore Delegato | - |
TransPharma Medical Ltd.
![]() TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Direttore operativo | - |
Formazione di Yael Kenen
Technion-Israel Institute of Technology | Masters Business Admin |
The Hebrew University of Jerusalem | Doctorate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
EPITOMEE MEDICAL LTD | Health Technology |
Aziende private | 2 |
---|---|
TransPharma Medical Ltd.
![]() TransPharma Medical Ltd. Pharmaceuticals: MajorHealth Technology Established in 2000, TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transversal drug delivery technology. Its current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transversal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1. TransPharma's drug-product development activities utilize its well-proven RF-MicroChannel Technology. Its RF-MicroChannel technology enables the creation of an array of microscopic pores through the very outer skin surface, allowing the delivery of therapeutic doses of a wide portfolio of drugs, including biologics, Its main area of focus. TransPharma's implementation of the RF-MicroChannel Technology is the ViaDerm delivery system. Intended for home use, the ViaDerm delivery system consists of a reusable, handheld, low-cost device and a disposable patch containing a drug. TransPharma's goal is to develop multiple drug-products through strategic partnerships with leading pharmaceutical companies and through independent product development. They believe that combining partnered and proprietary product development ensures capitalizing of both the promise of its technology and its growing capabilities. | Health Technology |
Lacrima Medical Ltd.
![]() Lacrima Medical Ltd. Medical SpecialtiesHealth Technology Lacrima Medical Ltd. engages in the development of medical device for the treatment of chronic insomnia. The company was founded in 2013 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Borsa valori
- Insiders
- Yael Kenen